Literature DB >> 22944306

Quality by design: impact of formulation variables and their interactions on quality attributes of a lyophilized monoclonal antibody.

David Awotwe-Otoo1, Cyrus Agarabi, Geoffrey K Wu, Elizabeth Casey, Erik Read, Scott Lute, Kurt A Brorson, Mansoor A Khan, Rakhi B Shah.   

Abstract

The purpose of this study was to use QbD approaches to evaluate the effect of several variables and their interactions on quality of a challenging model murine IgG3κ monoclonal antibody (mAb), and then to obtain an optimized formulation with predefined quality target product profile. This antibody was chosen because it has a propensity to precipitate and thus represents a challenge condition for formulation development. Preliminary experiments were conducted to rule out incompatible buffer systems for the mAb product quality. A fractional factorial experimental design was then applied to screen the effects of buffer type, pH and excipients such as sucrose, sodium chloride (NaCl), lactic acid and Polysorbate 20 on glass transition temperature ( [Formula: see text] ), monoclonal antibody concentration (A(280)), presence of aggregation, unfolding transition temperature (T(m)) of the lyophilized product, and particle size of the reconstituted product. A Box-Behnken experimental design was subsequently applied to study the main, interaction, and quadratic effects of these variables on the responses. Pareto ranking analyses showed that the three most important factors affecting the selected responses for this particular antibody were pH, NaCl, and Polysorbate 20. The presence of curvature in the variables' effects on responses indicated interactions. Based on the constraints set on the responses, a design space was identified for this mAb and confirmed with experiments at three different levels of the variables within the design space. The model indicated a combination of high pH (8) and NaCl (50mM) levels, and a low Polysorbate 20 (0.008 mM) level at which an optimal formulation of the mAb could be achieved. Moisture contents and other analytical procedures such as size exclusion chromatography, protein A analysis and SDS-PAGE of the pre-lyophilized and final reconstituted lyophilized products indicated an intact protein structure with minimal aggregation after formulation and lyophilization. In conclusion, experimental design approach was effective in identifying optimal concentrations of excipients and pH for this challenging monoclonal antibody formulation. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22944306     DOI: 10.1016/j.ijpharm.2012.08.033

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  9 in total

1.  Functionality of disintegrants and their mixtures in enabling fast disintegration of tablets by a quality by design approach.

Authors:  Parind Mahendrakumar Desai; Patrick Xuan Hua Er; Celine Valeria Liew; Paul Wan Sia Heng
Journal:  AAPS PharmSciTech       Date:  2014-05-22       Impact factor: 3.246

Review 2.  Understanding pharmaceutical quality by design.

Authors:  Lawrence X Yu; Gregory Amidon; Mansoor A Khan; Stephen W Hoag; James Polli; G K Raju; Janet Woodcock
Journal:  AAPS J       Date:  2014-05-23       Impact factor: 4.009

3.  Predicting Protein-Protein Interactions of Concentrated Antibody Solutions Using Dilute Solution Data and Coarse-Grained Molecular Models.

Authors:  Cesar Calero-Rubio; Ranendu Ghosh; Atul Saluja; Christopher J Roberts
Journal:  J Pharm Sci       Date:  2017-12-21       Impact factor: 3.534

4.  Characterization of the physical stability of a lyophilized IgG1 mAb after accelerated shipping-like stress.

Authors:  Srivalli Telikepalli; Ozan S Kumru; Jae Hyun Kim; Sangeeta B Joshi; Kristin B O'Berry; Angela W Blake-Haskins; Melissa D Perkins; C Russell Middaugh; David B Volkin
Journal:  J Pharm Sci       Date:  2014-12-17       Impact factor: 3.534

5.  Using simple models to describe the kinetics of growth, glucose consumption, and monoclonal antibody formation in naive and infliximab producer CHO cells.

Authors:  Julián López-Meza; Diana Araíz-Hernández; Leydi Maribel Carrillo-Cocom; Felipe López-Pacheco; María Del Refugio Rocha-Pizaña; Mario Moisés Alvarez
Journal:  Cytotechnology       Date:  2015-06-20       Impact factor: 2.058

6.  Double Optimization of Rivastigmine-Loaded Nanostructured Lipid Carriers (NLC) for Nose-to-Brain Delivery Using the Quality by Design (QbD) Approach: Formulation Variables and Instrumental Parameters.

Authors:  Sara Cunha; Cláudia Pina Costa; Joana A Loureiro; Jorge Alves; Andreia F Peixoto; Ben Forbes; José Manuel Sousa Lobo; Ana Catarina Silva
Journal:  Pharmaceutics       Date:  2020-06-28       Impact factor: 6.321

7.  Chitosan-dipotassium orthophosphate lyophilizate: a novel in situ thermogel carrier system of allogeneic platelet lysate growth factors.

Authors:  Toaa A Abdelrahman; Amira Motawea; Marwa S El-Dahhan; Galal M Abdelghani
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.419

8.  Improved Stability of a Model IgG3 by DoE-Based Evaluation of Buffer Formulations.

Authors:  Brittany K Chavez; Cyrus D Agarabi; Erik K Read; Michael T Boyne; Mansoor A Khan; Kurt A Brorson
Journal:  Biomed Res Int       Date:  2016-03-03       Impact factor: 3.411

9.  Identification of critical chemical modifications by size exclusion chromatography of stressed antibody-target complexes with competitive binding.

Authors:  Rachel Liuqing Shi; Gang Xiao; Thomas M Dillon; Arnold McAuley; Margaret S Ricci; Pavel V Bondarenko
Journal:  MAbs       Date:  2021 Jan-Dec       Impact factor: 5.857

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.